ImmunityBio, Inc. IBRX Increase in fair value of embedded conversion feature from debt modification
Increase in fair value of embedded conversion feature from debt modification at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative.
The official record: ImmunityBio, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s increase in fair value of embedded conversion feature from debt modification.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s increase in fair value of embedded conversion feature from debt modification?
- ImmunityBio, Inc. (IBRX) reported increase in fair value of embedded conversion feature from debt modification of $0 in Q4 2025.
- What does increase in fair value of embedded conversion feature from debt modification mean?
- The change in value of conversion options embedded in debt.
- How do you interpret increase in fair value of embedded conversion feature from debt modification?
- A gain indicates a decrease in the liability value, often due to changes in stock price or volatility assumptions.
- How does increase in fair value of embedded conversion feature from debt modification compare across companies?
- Common for companies with convertible debt featuring complex derivative components.